2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
4
Carcinoma, Non-Small-Cell Lung
3
Myelodysplastic Syndromes
2
Metastatic Solid Tumors
2
Melanoma
2
Solid Tumors
1
Recurrent Metastatic Non-Squamous Non Small Cell Lung Cancer
1
Recurrence
1
Prostate Cancer Patients Undergoing Radical Prostatectomy
1
Neoplasms
1
Neoadjuvant Treatment for Locally Advanced Cervical Cancer
1
Myeloproliferative Disorders
1
Lymphoma
1
Leukemia, Myelomonocytic, Chronic
1
Head and Neck Neoplasms
1
Glioma
1
Colorectal Neoplasms
1
Carcinoma, Hepatocellular
1
Cancer Pain
1
Breast Neoplasms
1
Breakthrough Pain
1
Biliary Tract Neoplasms
1
Advanced Malignant Neoplasm
1
Interventions
Cyclophosphamide
153
Dexamethasone
141
Rituximab
85
fludarabine
79
Lenalidomide
72
Cytarabine
70
Bortezomib
64
fludarabine phosphate
63
Gemcitabine
62
venetoclax
54
Etoposide
53
pomalidomide
52
pembrolizumab
52
Paclitaxel
48
Cisplatin
48
Carboplatin
48
Peripheral Blood Stem Cell Transplantation
47
Filgrastim
40
Radiotherapy
39
Busulfan
37
Calcium Dobesilate
36
Methotrexate
34
Melphalan
34
Bevacizumab
33
carfilzomib
32
Cyclosporine
32
Azacitidine
32
Mycophenolic Acid
30
Vincristine
29
Bendamustine Hydrochloride
29
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
Infusions, Intravenous
×
Clear all
NCT03850574
2025-08-26
TUSCANY
Aptose Biosciences Inc.
Phase 1/2
Recruiting
240 enrolled